Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.89 -3.5%	$2.72	$1.89 ▼ $4.12	$1.20B	0.62	3.45 million shs	5.21 million shs
CDXC ChromaDex		$6.16	$2.48 ▼ $9.18	$611.50M	2.21	818,872 shs	554,788 shs
DBVT DBV Technologies	$10.60 -3.7%	$9.48	$2.20 ▼ $12.78	$301.56M	-0.59	191,235 shs	18,640 shs
NUVB Nuvation Bio	$2.05 -1.4%	$2.14	$1.54 ▼ $3.97	$707.75M	1.33	2.98 million shs	4.72 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-3.47%	+11.46%	+59.43%	+79.26%	+41.45%
CDXC ChromaDex	0.00%	0.00%	0.00%	0.00%	+213.35%
DBVT DBV Technologies	-3.72%	+1.05%	+16.10%	+49.93%	+163.81%
NUVB Nuvation Bio	-1.44%	+5.94%	-17.00%	+15.17%	-34.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.5473 of 5 stars	3.5	1.0	0.0	3.1	3.3	0.0
CDXC ChromaDex	3.1895 of 5 stars	3.5	0.0	4.0	0.0	0.0	1.9
DBVT DBV Technologies	3.5933 of 5 stars	4.4	3.0	0.0	2.0	2.5	0.6
NUVB Nuvation Bio	3.4224 of 5 stars	4.6	0.0	0.0	3.2	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$7.50	92.80% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	39.15% Upside
NUVB Nuvation Bio	3.20	Buy	$7.17	249.59% Upside

Current Analyst Ratings Breakdown

Latest DBVT, CDXC, NUVB, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	40.27	N/A	N/A	$3.58 per share	1.09
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
DBVT DBV Technologies	$4.15M	69.96	N/A	N/A	$1.42 per share	7.46
NUVB Nuvation Bio	$7.87M	88.63	N/A	N/A	$1.37 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)

Latest DBVT, CDXC, NUVB, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/4/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
CDXC ChromaDex	N/A	2.95	2.35
DBVT DBV Technologies	N/A	0.72	0.72
NUVB Nuvation Bio	N/A	9.01	9.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CDXC ChromaDex	15.41%
DBVT DBV Technologies	71.74%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CDXC ChromaDex	9.64%
DBVT DBV Technologies	1.44%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable

DBVT, CDXC, NUVB, and ABCL Headlines

Recent News About These Companies

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Brokerages

July 7 at 4:10 AM | marketbeat.com

Nuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo Finance

July 2, 2025 | uk.finance.yahoo.com

Nuvation Bio (NYSE:NUVB) Stock Price Up 8% - Time to Buy?

June 30, 2025 | marketbeat.com

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

June 29, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume - Here's What Happened

June 25, 2025 | marketbeat.com

Nuvation Bio's (NUVB) "Market Outperform" Rating Reaffirmed at JMP Securities

June 25, 2025 | marketbeat.com

RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating

June 24, 2025 | msn.com

Nuvation Bio jumps after insiders purchase shares worth over $1.1M

June 20, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Shares Gap Up - Here's Why

June 20, 2025 | marketbeat.com

Founder of Nuvation Bio David Hung Buys More Stock

June 20, 2025 | finance.yahoo.com

Nuvation Bio price target lowered to $6 from $10 at RBC Capital

June 18, 2025 | investing.com

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements

June 18, 2025 | seekingalpha.com

Royal Bank of Canada Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price

June 17, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Shares Gap Down - Time to Sell?

June 16, 2025 | marketbeat.com

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

June 16, 2025 | globenewswire.com

Nuvation Bio price target maintained at $6 by Citizens JMP

June 14, 2025 | investing.com

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects

June 14, 2025 | investing.com

Nuvation Bio (NYSE:NUVB) Downgraded to "Sell" Rating by Wall Street Zen

June 14, 2025 | marketbeat.com

Nuvation Bio Stock Short Interest Report | NYSE:NUVB | Benzinga

June 13, 2025 | benzinga.com

US FDA approves Nuvation Bio's rare lung cancer drug

June 13, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Trading Down 5.5% - Here's What Happened

June 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, CDXC, NUVB, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.89 -0.14 (-3.47%)

Closing price 07/8/2025 04:00 PM Eastern

Extended Trading

$3.91 +0.02 (+0.51%)

As of 07/8/2025 07:57 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

DBV Technologies NASDAQ:DBVT

$10.60 -0.41 (-3.72%)

Closing price 07/8/2025 03:44 PM Eastern

Extended Trading

$10.72 +0.12 (+1.08%)

As of 07/8/2025 06:17 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Nuvation Bio NYSE:NUVB

$2.05 -0.03 (-1.44%)

Closing price 07/8/2025 03:59 PM Eastern

Extended Trading

$2.12 +0.07 (+3.41%)

As of 07/8/2025 07:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time